[1] Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev. 1998;11(4):589‐603.
[2] Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med. 2010 May 13;362(19):1804-13.
[3] Zimlichman E, Henderson D, Tamir O, Franz C, Song P, Yamin C. K. et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013;173(22):2039‐46.
[4] Feng DY, Zhou YQ, Zou XL, Zhou M, Wu WB, Chen XX, et al. Factors influencing mortality in hospital-acquired pneumonia caused by Gram-negative bacteria in China. J Infect Public Health. 2019 Sep - Oct;12(5):630-633.
[5] Versalovic J, Koeuth T, Lupski JR. Distribution of repetitive DNA sequences in
eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids
Res. 1991 Dec 25;19(24):6823-31.
[6] Dorneles EM, Santana JA, Ribeiro D, Dorella FA, Guimarães AS, Moawad MS, et al. Evaluation of ERIC-PCR as genotyping method for Corynebacterium pseudotuberculosis isolates. PLoS One. 2014 Jun 5;9(6):e98758.
[7] Miao M, Wen H, Xu P, Niu SQ, Lv JN, Xie XF, etc. Genetic Diversity of Carbapenem-Resistant Enterobacteriaceae (CRE) Clinical Isolates From a Tertiary Hospital in Eastern China. Front Microbiol. 2019 Jan 15;9:3341. [8] Zhang R, Liu L, Zhou H, Chan EW, Li YF, Li Y, et al. Nationwide Surveillance of Clinical Carbapenem-resistant Enterobacteriaceae (CRE) Strains in China. EBioMedicine. 2017 May;19:98-106.
[9] Pal A, Dhara L, Tripathi A. Contribution of acrB upregulation & OmpC/Ompk36 loss over the presence of blaNDM towards carbapenem resistance development among pathogenic Escherichia coli & Klebsiella spp. Indian J Med Res. 2019;149(4):528–38.
[10] Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrob Agents Chemother. 2010;54(3):969–976.
[11] Patel G, Bonomo RA. “Stormy waters ahead”: global emergence of carbapenemases. Front Microbiol. 2013;4:48.
[12] Opal SM, Pop-Vicas A, Molecular Mechanisms of Antibiotic Resistance in Bacteria. In: Bennett JE, Dolin R, BlaserMandell MJ, editors. Douglas, and Bennett's Principles and Practice of Infectious Diseases (Eighth Edition), 2015;235-51.
[13] Tamma PD, Hsu AJ. Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms. J Pediatric Infect Dis Soc. 2019;8(3):251‐60.
[14] Schroeder JW, Yeesin P, Simmons LA, Wang JD. Sources of spontaneous mutagenesis in bacteria. Crit Rev Biochem Mol Biol. 2018 Feb;53(1):29-48. [15] Andersson DI. Persistence of antibiotic resistant bacteria. Curr Opin Microbiol. 2003 Oct;6(5):452-6. [16] Bush K, Bradford PA. β-Lactams and β-Lactamase Inhibitors: An Overview. ColdSpring Harb Perspect Med. 2016 Aug 1;6(8).
[17] Gutiérrez-Gutiérrez B, Bonomo RA, Carmeli Y, Paterson DL, Almirante B, Martínez-Martínez L, et al. : Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. J Antimicrob Chemother. 2016;71(6):1672–80.
[18] Zhao YB, Qu XY, Yin C, Lu XF, Zhang Z, Yin AT. Clinical application of carbapenem antibiotics in tertiary general hospitals: a cross-sectional study[J]. Chinese Journal of Public Health, 2018, 34(2): 285-289.
[19] Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014 [J]. Clin Microbiol Infect. 2016;22(Suppl 1):S9–14.
[20] Chotiprasitsakul D, Srichatrapimuk S, Kirdlarp S, Pyden AD, Santanirand P. Epidemiology of carbapenem-resistant Enterobacteriaceae: a 5-year experience at a tertiary care hospital. Infect Drug Resist. 2019 Feb 20;12:461-8.
[21] Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis. 2014;14:13. Published 2014 Jan 9.
[22] Kohanski MA, DePristo MA, Collins JJ. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. Mol Cell. 2010;37(3):311–20.
[23] Hirayama S, Yasui K, Murakami H, Kosugi T, Sakamoto M, Hanai Y, et al. A new carbapenem drug dosage metric for carbapenem usage and correlation with carbapenem resistance of Pseudomonas aeruginosa. J Infect Chemother. 2018;24(12):949–53.
[24] Köck R, Daniels-Haardt I, Becker K, Mellmann A, Friedrich AW, Mevius D, et al. Carbapenem-resistant Enterobacteriaceae in wildlife, food-producing, and companion animals: a systematic review. Clin Microbiol Infect. 2018;24(12):1241–1250.
[25] Munita JM, Arias CA. Mechanisms of Antibiotic Resistance. Microbiol Spectr. 2016;4(2):10.1128/microbiolspec.VMBF-0016-2015.
[26] van Loon K, Voor In 't Holt AF, Vos MC. A Systematic Review and Meta-analyses
of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Dec 21; 62(1).
[27] Qiao M, Ying GG, Singer AC, Zhu YG. Review of antibiotic resistance in China and its environment. Environ Int. 2018;110:160–172.